Biocryst Pharmaceuticals Inc (BCRX) financials
Biocryst Pharmaceuticals revenue and earnings by year
Biocryst Pharmaceuticals's revenue was $875 million in the fiscal year to December 31, 2025, up 94.1% from the year before. Net income was $264 million, 30.2% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 47.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 875 | 451 | 331 | 271 | 157 | 18 | 49 | 21 | 25 | 26 |
| Revenue growth | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | -63.5% | 136.5% | -18.0% | -4.4% | — |
| Gross profit | 856 | 438 | 327 | 264 | 150 | 16 | 45 | 20 | 23 | 24 |
| Gross margin | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% | 90.6% | 91.6% | 97.7% | 93.2% | 89.8% |
| Operating income | 341 | -3 | -104 | -148 | -178 | -175 | -99 | -94 | -57 | -49 |
| Operating margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -227.9% | -184.4% |
| Net income | 264 | -89 | -227 | -247 | -184 | -183 | -109 | -101 | -66 | -55 |
| Net margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.3% | -261.2% | -209.3% |
| Diluted EPS | $1.21 | -$0.43 | -$1.18 | -$1.33 | -$1.03 | -$1.09 | -$0.94 | -$0.98 | -$0.78 | -$0.75 |
| Free cash flow | 345 | -53 | -97 | -163 | -145 | -136 | -90 | -93 | -41 | -59 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BCRX in Markets.
How Biocryst Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| ORLADEYO | $158M | 72.5% |
| License Revenue & Other Income From Contract With Customer | $60.0M | 27.5% |
See also: BCRX returns
No forecast, no recommendation. This page describes Biocryst Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.